Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Riassunto: Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals has announced new data at the ESC 2026 Congress, showcasing the effectiveness of RNAi-based silencing in treating cardiovascular diseases, particularly in patients with ATTR-CM. This presentation reinforces the company's leadership in RNAi therapies and their potential impact on patient care. The findings contribute to the ongoing dialogue in cardiovascular treatment advancements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam presents new data demonstrating RNAi technology's effectiveness.
  • The findings support treatment for patients with ATTR-CM.
  • The presentation at ESC 2026 highlights advancements in cardiovascular therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), l'azienda leader nelle terapie RNAi, oggi ha annunciato nuovi dati al Congresso della European Society of Cardiology (ESC) 2026 che dimostrano l'efficacia del silenziamento basato sulla tecnologia RNAi nelle malattie cardiovascolari. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono

Frequently Asked Questions

What new data did Alnylam present at ESC 2026?

Alnylam presented new data demonstrating the effectiveness of RNAi-based silencing in treating cardiovascular diseases.

What is the focus of Alnylam's research?

Alnylam focuses on RNAi therapies, particularly for patients with ATTR-CM.

Why is the ESC 2026 Congress significant for Alnylam?

The ESC 2026 Congress is significant as it showcases Alnylam's advancements in RNAi technology and its impact on cardiovascular treatment.

What condition is primarily addressed by Alnylam's new data?

Alnylam's new data primarily addresses the treatment of ATTR-CM in patients.

ShareAdd on Google
Tags: ALNY Viatris Investor Conferences Healthcare Alnylam RNAi ATTR-CM ESC 2026 cardiovascular diseases
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+25%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →